



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pollak <i>et al.</i>	§	ART UNIT:
		§ 1642
FILED: December 18, 2001	§	
		§ EXAMINER:
SERIAL NO.: 10/025,350	§	Holleran, Anne L.
		§
FOR: Circulating Insulin-Like Growth Factor-I §	§	DOCKET:
and Prostate Cancer Risk	§	28758.57

Mail Stop Non-Fee Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE UNDER 37 CFR 1.111

Dear Sir:

In response to the Office Action mailed October 5, 2004 please consider the following remarks. Reconsideration of the pending claims is respectfully requested.

REMARKS

Status of the Claims

Claims 21-27 are pending. Claims 21-27 are rejected.

The 35 U.S.C. §112, first paragraph rejections

Claims 21-27 are rejected under 35 U.S.C. §112, first paragraph, as lacking enablement because the specification does not enable any person skilled in the art to